The Emerging Role of Gut Microbiome Dysbiosis in Atherosclerosis Development Through TMAO and Other Metabolic Pathways
The gut microbiome has emerged as an unexpected contributor to atherosclerosis through production of metabolites that influence cardiovascular risk, fundamentally changing our understanding of disease mechanisms. Trimethylamine N-oxide (TMAO), produced when gut bacteria metabolize dietary choline, phosphatidylcholine, and L-carnitine found predominantly in red meat, eggs, and high-fat dairy, has shown strong associations with atherosclerotic disease and cardiovascular events. TMAO enhances foam cell formation, promotes platelet hyperreactivity, and increases inflammation, creating multiple atherogenic effects independent of traditional risk factors.
Microbiome composition varies dramatically between individuals based on diet, medications, and environmental exposures, with beneficial bacteria producing short-chain fatty acids that reduce inflammation while pathogenic bacteria generate harmful metabolites. This discovery explains why two individuals with identical cholesterol levels may have vastly different cardiovascular outcomes based on their microbiome profile and diet composition. Therapeutic strategies targeting the microbiome including probiotics, prebiotics, dietary modification to reduce TMAO precursors, and potentially microbiome transplantation represent…